Abstract
INTRODUCTION: Coronavirus disease 2019 (COVID-19) emerged as a global pandemic and resulted in a significantly high death toll. Therefore, there is an urgent need to find a potential biomarker related to the disease severity that can facilitate early-stage intervention. METHODS: In the present study, we collected 242 laboratory-confirmed COVID-19-infected patients. The patients were grouped according to the alveolar to arterial oxygen tension difference (P(A-a)O(2)) value of COVID-19 infection after admission. RESULTS: Among the 242 laboratory-confirmed COVID-19- infected patients, 155 (64.05%) had an abnormal P(A-a)O(2) value on admission. Compared with the normal P(A-a)O(2) group, the median age of the abnormal P(A-a)O(2) group was significantly older (p = 0.032). Symptoms such as fever, cough, and shortness of breath were more obvious in the abnormal P(A-a)O(2) group. The proportion of severe events in the abnormal P(A-a)O(2) group was higher than the normal P(A-a)O(2) group (10.34% vs. 23.23%, p = 0.013). The abnormal P(A-a)O(2) group had a higher possibility of developing severe events compared with the normal P(A-a)O(2) group (HR 2.622, 95% CI 1.197-5.744, p = 0.016). After adjusting for age and common comorbidities (hypertension and cardiovascular disease), the abnormal P(A-a)O(2) group still exhibited significantly elevated risks of developing severe events than the normal P(A-a)O(2) group (HR 2.986, 95% CI 1.220-7.309, p = 0.017). Additionally, the abnormal P(A-a)O(2) group had more serious inflammation/coagulopathy/fibrinolysis parameters than the normal P(A-a)O(2) group. CONCLUSION: Abnormal P(A-a)O(2) value was found to be common in COVID-19 patients, was strongly related to severe event development, and could be a potential biomarker for the prognosis of COVID-19 patients.